In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Why?

In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Why?

In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Why?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Tom Huizinga, MD, PhD

Professor Tom Huizinga, MD, PhD

Head, Department of Rheumatology
Leiden University Medical Center
Leiden, The Netherlands